Trial document

PLEASE NOTE:
This study has been imported from ClinicalTrials.gov without additional data checks.

drksid header

DRKS-ID: DRKS00008822

Trial Description

start of 1:1-Block title

Title

Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

This study will evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of
urinary incontinence due to neurogenic detrusor overactivity in pediatric patients between
the ages of 8 to 17 years.

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

[---]*

end of 1:1-Block scientific synopsis

start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data

start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00008822
Date of Registration in DRKS: 2015/08/11
Date of Registration in Partner Registry or other Primary Registry: 2013/05/09
Investigator Sponsored/Initiated Trial (IST/IIT): no
Ethics Approval/Approval of the Ethics Committee: [---]*
(leading) Ethics Committee No.: [---]*

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

EudraCT-No. (for studies acc. to Drug Law): 2012-004877-26
Primary Registry-ID: NCT01852045 (ClinicalTrials.gov)
Sponsor-ID: 191622-120 (Allergan)
Other Secondary-ID: 2012-004877-26

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

Free text: Urinary Incontinence
ICD10: R32 - Unspecified urinary incontinence

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

Arm 1: Biological: OnabotulinumtoxinA

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Interventional
Study Type Non-Interventional: [---]*
Allocation: Randomized controlled trial
Blinding: Blinded
Who is blinded: patient/subject, caregiver, investigator/therapist, assessor
Control: [---]*
Purpose: Treatment
Assignment: Parallel
Phase: III
Off-label Drug use: [---]*

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

- Change from Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes; time frame: Baseline, 6 Weeks

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

- Change from Baseline in Maximum Cystometric Capacity (MCC); time frame: Baseline, Week 6
- Percentage of Patients With Involuntary Detrusor Contractions (IDC); time frame: Week 6
- Change from Baseline in Maximum Detrusor Pressure During the First IDC; time frame: Baseline, Week 6
- Change from Baseline in Detrusor Leak Point Pressure (DLPP); time frame: Baseline, Week 6
- Change from Baseline in Average Urine Volume at First Morning Catheterization; time frame: Baseline, 6 Weeks
- Percentage of Patients With Night Time Urinary Incontinence; time frame: 6 Weeks
- Change from Baseline in Maximum Detrusor Pressure; time frame: Baseline, Week 6
- Time to Patient Request for Retreatment; time frame: 48 Weeks
- Time to Patient Qualification for Retreatment; time frame: 48 Weeks

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

US: United States
AT: Austria
BE: Belgium
CA: Canada
CZ: Czech Republic
FR: France
DE: Germany
IT: Italy
PL: Poland
TR: Turkey

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

Berlin

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: [---]*
(Anticipated or Actual) Date of First Enrollment: 2013/06/30
Target Sample Size: 132
Monocenter/Multicenter trial: Multicenter trial
National/International: International

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: 8 Years
Maximum Age: 17 Years

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Urinary incontinence due to neurogenic detrusor overactivity

- Regularly using clean intermittent catheterization to empty the bladder

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

- Surgery of the spinal cord within 6 months

- Diagnosis of cerebral palsy

- Current or planned use of a baclofen pump

- Current or planned use of an electrostimulation/neuromodulation device for urinary
incontinence

- Use of an indwelling catheter for urinary incontinence instead of using clean
intermittent catheterization to empty the bladder

- Previous or current use of botulinum toxin therapy of any serotype for any urological
condition, or treatment with botulinum toxin of any serotype within 3 months for any
other condition or use

- Myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- Allergan
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact primary-sponsor
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- Allergan
- Medical Director
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Allergan Inc.
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: [---]*
- Fax: [---]*
- E-mail: clinicaltrials at allergan.com
- URL: [---]*
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

[---]*
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact materialSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting ongoing
Study Closing (LPLV): [---]*

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

Further trial documents: More information

end of 1:n-Block publications

The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .

Translation on version: 3
Last processed date by ClinicalTrials.gov: 2016/01/14

Please note:
There are additional attributes available concerning this trial. To open an extended view please click here .

* This entry means the parameter is not applicable or has not been set.